Cargando…

Stem cell therapies for autoimmune hepatitis

Autoimmune hepatitis is a chronic inflammatory hepatic disorder which may cause liver fibrosis. Appropriate treatment of autoimmune hepatitis is therefore important. Adult stem cells have been investigated as therapies for a variety of disorders in latest years. Hematopoietic stem cells (HSCs) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotfy, Ahmed, Elgamal, Aya, Burdzinska, Anna, Swelum, Ayman A., Soliman, Reham, Hassan, Ayman A., Shiha, Gamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262021/
https://www.ncbi.nlm.nih.gov/pubmed/34233726
http://dx.doi.org/10.1186/s13287-021-02464-w
_version_ 1783719114366255104
author Lotfy, Ahmed
Elgamal, Aya
Burdzinska, Anna
Swelum, Ayman A.
Soliman, Reham
Hassan, Ayman A.
Shiha, Gamal
author_facet Lotfy, Ahmed
Elgamal, Aya
Burdzinska, Anna
Swelum, Ayman A.
Soliman, Reham
Hassan, Ayman A.
Shiha, Gamal
author_sort Lotfy, Ahmed
collection PubMed
description Autoimmune hepatitis is a chronic inflammatory hepatic disorder which may cause liver fibrosis. Appropriate treatment of autoimmune hepatitis is therefore important. Adult stem cells have been investigated as therapies for a variety of disorders in latest years. Hematopoietic stem cells (HSCs) were the first known adult stem cells (ASCs) and can give rise to all of the cell types in the blood and immune system. Originally, HSC transplantation was served as a therapy for hematological malignancies, but more recently researchers have found the treatment to have positive effects in autoimmune diseases such as multiple sclerosis. Mesenchymal stem cells (MSCs) are ASCs which can be extracted from different tissues, such as bone marrow, adipose tissue, umbilical cord, and dental pulp. MSCs interact with several immune response pathways either by direct cell-to-cell interactions or by the secretion of soluble factors. These characteristics make MSCs potentially valuable as a therapy for autoimmune diseases. Both ASC and ASC-derived exosomes have been investigated as a therapy for autoimmune hepatitis. This review aims to summarize studies focused on the effects of ASCs and their products on autoimmune hepatitis.
format Online
Article
Text
id pubmed-8262021
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82620212021-07-07 Stem cell therapies for autoimmune hepatitis Lotfy, Ahmed Elgamal, Aya Burdzinska, Anna Swelum, Ayman A. Soliman, Reham Hassan, Ayman A. Shiha, Gamal Stem Cell Res Ther Review Autoimmune hepatitis is a chronic inflammatory hepatic disorder which may cause liver fibrosis. Appropriate treatment of autoimmune hepatitis is therefore important. Adult stem cells have been investigated as therapies for a variety of disorders in latest years. Hematopoietic stem cells (HSCs) were the first known adult stem cells (ASCs) and can give rise to all of the cell types in the blood and immune system. Originally, HSC transplantation was served as a therapy for hematological malignancies, but more recently researchers have found the treatment to have positive effects in autoimmune diseases such as multiple sclerosis. Mesenchymal stem cells (MSCs) are ASCs which can be extracted from different tissues, such as bone marrow, adipose tissue, umbilical cord, and dental pulp. MSCs interact with several immune response pathways either by direct cell-to-cell interactions or by the secretion of soluble factors. These characteristics make MSCs potentially valuable as a therapy for autoimmune diseases. Both ASC and ASC-derived exosomes have been investigated as a therapy for autoimmune hepatitis. This review aims to summarize studies focused on the effects of ASCs and their products on autoimmune hepatitis. BioMed Central 2021-07-07 /pmc/articles/PMC8262021/ /pubmed/34233726 http://dx.doi.org/10.1186/s13287-021-02464-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Lotfy, Ahmed
Elgamal, Aya
Burdzinska, Anna
Swelum, Ayman A.
Soliman, Reham
Hassan, Ayman A.
Shiha, Gamal
Stem cell therapies for autoimmune hepatitis
title Stem cell therapies for autoimmune hepatitis
title_full Stem cell therapies for autoimmune hepatitis
title_fullStr Stem cell therapies for autoimmune hepatitis
title_full_unstemmed Stem cell therapies for autoimmune hepatitis
title_short Stem cell therapies for autoimmune hepatitis
title_sort stem cell therapies for autoimmune hepatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262021/
https://www.ncbi.nlm.nih.gov/pubmed/34233726
http://dx.doi.org/10.1186/s13287-021-02464-w
work_keys_str_mv AT lotfyahmed stemcelltherapiesforautoimmunehepatitis
AT elgamalaya stemcelltherapiesforautoimmunehepatitis
AT burdzinskaanna stemcelltherapiesforautoimmunehepatitis
AT swelumaymana stemcelltherapiesforautoimmunehepatitis
AT solimanreham stemcelltherapiesforautoimmunehepatitis
AT hassanaymana stemcelltherapiesforautoimmunehepatitis
AT shihagamal stemcelltherapiesforautoimmunehepatitis